These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30476963)

  • 1. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
    Roukens AHE; van Halem K; de Visser AW; Visser LG
    Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
    Roukens AH; Vossen AC; Bredenbeek PJ; van Dissel JT; Visser LG
    PLoS One; 2008 Apr; 3(4):e1993. PubMed ID: 18431480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
    Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
    J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
    Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
    N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2019 Aug; 37(35):5129-5135. PubMed ID: 31171393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
    Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
    Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
    Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Kimathi D; Juan-Giner A; Orindi B; Grantz KH; Bob NS; Cheruiyot S; Hamaluba M; Kamau N; Fall G; Dia M; Mosobo M; Moki F; Kiogora K; Chirro O; Thiong'o A; Mwendwa J; Guantai A; Karanja HK; Gitonga J; Mugo D; Ramko K; Faye O; Sanders EJ; Grais RF; Bejon P; Warimwe GM
    Lancet Infect Dis; 2023 Aug; 23(8):974-982. PubMed ID: 37127045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
    Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
    J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Juan-Giner A; Namulwana ML; Kimathi D; Grantz KH; Fall G; Dia M; Bob NS; Sall AA; Nerima C; Sahani MK; Mulogo EM; Ampeire I; Hombach J; Nanjebe D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
    Lancet Infect Dis; 2023 Aug; 23(8):965-973. PubMed ID: 37127047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractional-dose yellow fever vaccination: how much more can we do with less?
    Visser LG
    Curr Opin Infect Dis; 2019 Oct; 32(5):390-393. PubMed ID: 31335440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
    Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
    Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
    Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F;
    AIDS; 2018 Oct; 32(16):2291-2299. PubMed ID: 30096071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractional-dose yellow fever vaccination: an expert review.
    Roukens AHE; Visser LG
    J Travel Med; 2019 Sep; 26(6):. PubMed ID: 30937437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.
    Wieten RW; Jonker EF; Pieren DK; Hodiamont CJ; van Thiel PP; van Gorp EC; de Visser AW; Grobusch MP; Visser LG; Goorhuis A
    Vaccine; 2016 Mar; 34(10):1247-51. PubMed ID: 26845742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.